➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
Harvard Business School
Medtronic
AstraZeneca
Johnson and Johnson

Last Updated: July 6, 2020

DrugPatentWatch Database Preview

ALBURX Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Summary for Tradename: ALBURX
Recent Litigation for ALBURX

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
ABRAXIS BIOSCIENCE, LLC v. SUN PHARMA ADVANCED RESEARCH COMPANY, LTD.2019-08-08
Genentech, Inc. v. Pfizer Inc.2019-04-05
Abraxis BioScience, LLC v. HBT Labs, Inc.2018-12-19

See all ALBURX litigation

PTAB Litigation
PetitionerDate
2017-11-09
Cipla Ltd.2017-11-09
Actavis LLC2017-04-04

See all ALBURX litigation

Patent Text Search: US Patents for ALBURX

These patents were identified by searching patent claims

Supplementary Protection Certificates for ALBURX

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C20140031 00119 Estonia   Start Trial PRODUCT NAME: ALBIGLUTIID;REG NO/DATE: K(2014)2052 (LOPLIK) 26.03.2014
37/2014 Austria   Start Trial PRODUCT NAME: PACLITAXEL, DAS ALS ALBUMIN GEBUNDENE NANOPARTIKEL FORMUIERT IST.; REGISTRATION NO/DATE: EU/1/07/428 (MITTEILUNG) (GEAENDERT DURCH C(2013) 9835) 20131230
122014000065 Germany   Start Trial PRODUCT NAME: PACLITAXEL ALS AN ALBUMIN GEBUNDENE NANOPARTIKEL-FORMULIERUNG; REGISTRATION NO/DATE: K(2013)9835 20131220
1490056-7 Sweden   Start Trial PRODUCT NAME: ALBIGLUTIDE; REG. NO/DATE: EU/1/13/908/001002 20140321
C300691 Netherlands   Start Trial PRODUCT NAME: ALBUMINE-FUSIE-EIWIT MET GLUCAGONACHTIG-PEPTIDE 1 (GLP-1)-ACTIVITEIT, OMVATTENDE TWEE TANDEMSGEWIJS GEORIENTEERDE AAN ALBUMINE GEFUSEERDE GLP-1-POLYPEPTIDEN, ZOALS GESPECIFICEERD IN DELEN (I) EN (II) VAN CONCLUSIE 1 VAN EP1463751; ZOALS EEN ALBUMINE-FUSIE-EIWIT MET GLUCAGONACHTIG-PEPTIDE 1 (GLP-1)-ACTIVITEIT, OMVATTENDE TWEE TANDEMSGEWIJS GEORIENTEERDE AAN ALBUMINE GEFUSEERDE GLP-1 (7-36(A8G))-POLYPEPTIDEN, ZOALS EEN ALBUMINE-FUSIE-EIWIT MET GLUCAGONACHTIG-PEPTIDE 1 (GLP-1)-ACTIVITEIT, OMVATTENDE TWEE TANDEMSGEWIJS GEORIENTEERDE AAN HUMAAN SERUM ALBUMINE GEFUSEERDE GLP-1)7-36(A8G))-POLYPEPTIDEN, ZOALS EEN ALBUMIDEFUSIE MET GLUCAGONACHTIG-PEPTIDE 1 (GLP-1)-ACTIVITEIT, OMVATTENDE
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
Boehringer Ingelheim
AstraZeneca
Mallinckrodt
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.